<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0002621'>Atherosclerosis</z:hpo> is an important clinical problem in patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), because of very severe cardiovascular and central <z:mp ids='MP_0008912'>nervous</z:mp> system manifestations </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVES: Estimation if <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) and <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) are risk factors for subclinical <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in patients with SLE </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: We examined 103 patients with SLE and 30 healthy volunteers, included as the control group </plain></SENT>
<SENT sid="3" pm="."><plain>Coexistence of APS was confirmed in 35 patients </plain></SENT>
<SENT sid="4" pm="."><plain>Evaluation of subclinical <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> was done on the basis of measurement of intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>) in B-mode ultrasound examination </plain></SENT>
<SENT sid="5" pm="."><plain>We considered classical atherosclerotic risk factors and determined profile of aPL: anti-cardiolipine antibodies (aCL), anti beta2 <z:chebi fb="2" ids="17089">glycoprotein</z:chebi>-I antibodies, antiprothrombin antibodies (aPT), anti-oxidized <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> antibodies and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) </plain></SENT>
<SENT sid="6" pm="."><plain>Statistical analysis was performed with chi2 Yates, chi2 Pearson and R rang Spearman tests </plain></SENT>
<SENT sid="7" pm="."><plain>Multivariate regression analysis was also done </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Thickened <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> was significantly more frequent in patients with SLE than in controls (p = 0.0002) </plain></SENT>
<SENT sid="9" pm="."><plain>We found that coexistence of APS is a risk factor for moderate thickening of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> (OR: 3.41; 95% CI: 1.0-11.5) </plain></SENT>
<SENT sid="10" pm="."><plain>We also confirmed that the presence of aPL is significantly correlated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> ranging from 0.66 to 0.86 mm </plain></SENT>
<SENT sid="11" pm="."><plain>The highest risk was found in patients with the presence of aPT IgA (OR: 5.50; 95% CI: 1.1-30.2), aCL IgM (OR: 4.36; 95% CI: 1.1-20.7), LA (OR: 4.02; 95% CI: 1.1-19.4) and aCL IgG (OR: 2.99; 95% CI: 1.1-9.7) </plain></SENT>
<SENT sid="12" pm="."><plain>Moreover, we found that <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischaemic heart disease</z:e>, <z:hpo ids='HP_0000112'>nephropathy</z:hpo> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> were significantly more frequent in patients with thickened <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Patients with SLE develop subclinical <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> significantly more frequent than the general population </plain></SENT>
<SENT sid="14" pm="."><plain>Coexistence of APS and presence of aPL are risk factors for subclinical <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> development in patients with SLE </plain></SENT>
<SENT sid="15" pm="."><plain>Thickened intima-media in patients with SLE is significantly associated with an increased risk of cardiovascular manifestations </plain></SENT>
</text></document>